DAFTAR PUSTAKA
Agamah ES, Srinivasan SR, Webber LS, Berenson GS (1991): Serum uric acid and its relations to cardiovascular disease risk factors in children and young adults from a biracial community: The Bogalusa Heart Study. J Lab Clin Med, 118:241-249.
Alderman MH, Cohen H, et al (1999). Serum Uric Acid and Cardiovascular Events in Successfully Treated Hypertensive Patients. Hypertension, 34:144-150
Alderman, MH (2007). Uric Acid and Cardiovascular Disease. Circulation: 880-83.
Aminullah A, Rukman Y, Munasir Z, Sastroasmoro S (2007). Variabel dan Hubungan antar Variabel. In: Sastroasmoro S dan Ismael S (ed). Dasar –Dasar Metodologi Penelitian Klinis Edisi Ketiga. Jakarta: Sagung Seto , 255-78.
Bakri S, Lawrences (2008). Genetika Hipertensi, dalam Hipertensi dan Ginjal, 19-31.
Becker & Meenaskshi J. Clinical gout and pathogenesis of hyperuricaemia (2005). In Arthritis and Allied Conditions. A Textbook of Rheumatology Ed-13. Baltimore. Williams & Wilkins a Wavelry comp, 2303-2339.
Beevers G,Lip GY,et al (2001). ABC of hypertension (The pathophysiology of hypertension). BMJ, 322 : 912-916.
Berry CE and JM Hare (2004). Xanthine Oxidoreductase and Cardiovascular Disease: Molecular Mechanism and Pathophysiological Implications. Am J Physiol : 589-606.
Blumenfeld JD and Laragh JH (2008). Hypertension and the kidney from Brenner and Rector’s. The Kidney Ed-8, 1465-1516.
Bradlow A (1998). Symptomless hyperuricaemia in patients with essential hypertension and normal renal function. Journal of Human Hypertension, 12: 147-148.
Brown MJ, Palmer CR, Casteigne A. Morbidity and mortality in patients randomized to double blind treatment with a long acting calcium channel blocker or diuretic in the International Nifedipine GITS Study : Intervention as a Goal in Hypertension Treatment (INSIGHT) (2000). Lancet ;536: 366-372.
Campo C, Ruilope LM, Segura J (2001). Serum urate as a marker of hypertension severity. J Hypertension, in press.
Canon PJ, Stason WB, Demartini FE, Laragh JH, Sommers SC (1966). Hyperuricemia in primary and renal hypertension. New England Journal of Medicine ; 275:457-464.
Cohen MG, Emmerson BT (1994). Gout in Rheumatology, JH Klippel, PA Dippe (eds), Part 2. St Louis Baltimore. Mosby : 12.1-12.16.
Conen D, Wietlisbach V, et al (2004). Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health, 4:1-9.
Cooper RS, Tayo B (2008). Hypertension Primer: The Essentials of High Blood Pressure : Basic Science, Population Science, Clinical Management by Izzo JL, Sica DA, Black HR (eds) Ed-4. Lippincott Williams & Wilkins, B (74): 240-242.
Culleton BF, Larson MG, Kannel WB, Levy D (2006).Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med, 131:7-13.
Emmerson, BT (1983). Hyperuricaemia and Gout in Clinical Practice. ADIS Health SciencePress, Sidney.
Feig DI, Kang DH, Johnson RJ (2008). Uric Acid and Cardiovascular Risk. N Eng J Med: 1811-21.
Feig DI. Uric Acid and Hypertension (2011). Semin Nephrol, 31: 441-446.
Fessel WJ (1979). Renal outcomes of gout and hyperuricemia. American journal of medicine, 67: 74 - 82.
Goldstein HS, Manowitz P (1993). Relation between serum uric acid and blood pressure in adolescents. Annals of Hum Biology, 20(5): 423- 431.
Hayden MR, Tyagi SC (2004). Uric Acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutrition & Metabolism, I ;10: 1-15.
Hediger MA, Johnson RJ, Miyazaki H, EndouH (2005). Molecular Physiology of Urate Transport. Am J Physiol :125-33.
Heinig M and RJ Johnson (2006). Role of Uric Acid in Hypertension, Renal Disease, and Metabolic Syndrome. Cleveland Clinic Journal of Medicine :1059-64.
Iseki K, Oshiro S, et al (2001). Significance of Hyperuricemia on the Early Detection of Renal Failure in a Cohort of Screened Subjects. Hypertension Res, 24:691-697.
Johnson RJ, Kang DH, Feig D, Kivlighn S, Kannelis J, Watanabe S, Tuttle KR (2003). Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension, 41:1183-1190.
Johnson RJ, Segal MS,Srinivas T, et al (2005) . Essensial Hypertension, Progressive Renal Disease, and Uric Acid: A Pathogenic Link? J Am Soc Nephrol, 16:1909-1919.
Kaplan NM (2002). Primary Hypertension: pathogenesis. Kaplan’s clinical hypertension. Ed-8 Philadelphia. Lippincott Williams & Willkins, 56-135.
Kelly WN, Wortmann RL (1997). Crystal-associated synovitis: gout and hyperuricemia. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of rheumatology. Ed-5 Philadelphia. WB Saunders, 1313-47.
Kinsey D, Walther R, Wise HS, Smithwick R (1961). Incidence of hyperuricemia in 400 hypertensive patients” Circulation, 24:972.
Kolbel F, Gregorova I, Souka J. Serum uric acid in hypertensives (1965). Lancet, 1; 519.
Kumar A, Singh YN, Malaviya AN, Chaudhary K, Tripathy S (1990). Clinical profile, therapeutic approach and outcome of gouty arthritis in northern India. Journal of Association of Physicians of India, June, 38(6): 400-402.
Lawrence GS (2010). Implikasi Klinis Disfungsi Endotel dan Radikal Bebas. Makassar: FK UNHAS.
Lehto S, Niskanen L, Ronnemma T, Laakso M (1998). Serum Uric Acid is A Strong Predictor of Stroke in Patients with Non-Insulin Dependent Diabetes Mellitus. Stroke : 635-39.
Lippi G, Targher G, et al (2008). High Serum Uric Acid and a Novel Risk Factor for Type 2 Diabetes. Diabetes Care, 31(9) : e 68.
Madiyono B, Moeslichan S, Sastroasmoro S, Budiman I, Purwanto SH (2007). Perkiraan Besar Sampel. In: Sastroasmoro S dan Ismael S (ed). Dasar –Dasar Metodologi Penelitian Klinis Edisi Ketiga. Jakarta: Sagung Seto, 302-30.
Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, et al (2010). Uric Acid and Hypertension : Cause or Effect? Current Rheumatol, 12:108-117.
Mei Z, Ying F. An Analysis on the relationship between essensial hypertension and hyperuricemia (2002). China Academic Journal Publishing House, 27 (3):223-226.
Melander O (2001). Genetic Factors in Hypertension- What is known and What Does It Mean? Blood Pressure, 10 : 254-270.
Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG (1980). Serum Uric Acid in Essential Hypertension: an indicator of renal vascular involvement. Annals of Internal Medicine, 93:817-821
Mladinescu OF, Savoiu G, Serban C, Noveanu L, Gaita D, Muntean D (2008). The Rule of Hyperurisemia in Endothelial Dysfunction Induced by Hypertension. Romanian J. Biophys : 329-36.
Nakagawa T,Kang DH (2006). Unearthing uric acid: An ancient factor with recently found significance in renal and cardiovascular disease. Kidney International, 69: 1722-1725.
Niskanen L, Laaksonen DE (2006). Serum Uric Acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance, The Finnish Diabetes Prevention Study. Diabetes Care, 29: 709-711.
Niskanen LK, Laaksonen DE, Nyysonen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT (2004). Uric Acid Level as a Risk Factor for Cardiovascular and All Cause Mortality in Middle Aged Men: A Prospective Cohort Study. Arch Itern Med, :1541-46.
Obermayr RP, Temml C, et al (2008). Elevated Uric Acid Increases the Risk for Kidney Disease. Clinical Epidemiology. J Am Soc Nephrol :1-7.
Oparil S, Zaman MA, et al (2003). Pathogenesis of hypertension. Ann Intern Med, 139:761-776.
Purwanto, Bambang (2009). Pathogenesis, Etiology, and Management of Hypertension and Nefrotoxic Agents. Disampaikan pada Half Day Simposium: Renal Disease Induced by Nefrotoxic Agents. Surakarta.
Putra, Tjokorda Raka (2006). Hiperurisemia. In: Sudoyo dkk (ed). Buku Ajar Ilmu Peyakit Dalam Jilid II Edisi IV. Jakarta: FKUI : 1213-17.
Riskerdas R (2007). Prevalensi Penyakit Kronis ( Persendian, Hipertensi, Stroke pada Penduduk) dalam 1 tahun terakhir Menurut Karakteristik Responden di NAD: 79-80.
Ruilope LM and Rodicio JL (2001). The Kidney in Arterial Hypertension. Nephrol Dial Transplant, 16 (Suppl 1): 50-52.
Ruilope LM, Lahera V, Rodicio JL, Romero JC (1994). Are renal hemodynamics a key factor in the development and maintanance of arterial hypertension in humans? Hypertension 1994;23:3-9.
Ruilope LM (2001). Kidney function, a sensitive predictor of cardiovascular risk. Am J Hypertension, in press.
Savoiu G, Serban C, et al (2008). The Role of Hyperuricemia in Endothelial Dysfunction Induced by Hypertension. Romanian J. Biophys, 18 (4): 329-336.
Schumacer Jr HR. Hyperuricaemia and Gout (1992). In Rheumatology APLAR, 243-293.
The Seventh Report on the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (2004). NIH Publication No. 04-5230, August
Tykarski A. Evaluation of renal handling of uric acid in essential hypertension; hyperuricemia related to decreased urate secretion. Nephrology 1991, 59(3) : 364-368.
Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Brunetti P (2000). Relation between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension. The PIUMA Study Hypertension : 1072-78.
Viazzi F, Leoncini G, et al (2007). Mild Hyperuricemia and Subclinical Renal Damage in Untreated Primary Hypertension. American Journal of Hypertension, 20: 1276-1282.
Waring WS, Esmail S (2005). How Should Serum Uric Acid Concentration be Interpreted in Patients with Hypertension. Current Hypertension Reviews : 89-95.
Waring WS, Webb D, Maxwell SRJ (2000). Uric acid as a risk factor for cardiovascular disease. Q J Med, 93: 707-713.
Wisesa IBN, Suastika K (2009). Hubungan antara konsentrasi Asam Urat Serum dengan Resistensi Insulin Pada Penduduk Suku Bali Asli Di Dusun Tenganan Pengringsingan Karangasem. J.Peny. Dalam, vol. 10 (2) Mei : 110-122
Yeon HK, Yeong DS, Sung PS (1986). Observation of the serum uric acid in essential hypertension. The Korean Journal of Internal Medicine, 1(1) : 14-20.
Yogiantoro, Mohammad (2006). Hipertensi Esensial. In: Sudoyo dkk (ed). Buku Ajar Ilmu Peyakit Dalam Jilid I Edisi IV Jakarta FKUI : 610-14
Yongkuan W, Meijing L, Jue L (2008). Elevated serum uric acid level as predictor for cardiovascular and all cause mortality in Chinese patients with high cardiovascular risk. Journal of Geriatric Cardiology, 5:15-20.
